February 2026 Research Update

This month, studies added practical clues about how CAH monitoring might be made more consistent and less burdensome, especially for children. One study in children with 21-hydroxylase CAH linked everyday measures like growth and a key androgen blood test to bone age patterns, while another study showed that saliva hormone testing often tracked well with blood levels. A separate validation study suggested an automated bone age tool can be accurate even in children with growth disorders that include CAH, which could eventually reduce variability between human readers. [1] [2] [3]

In 96 children with 21-hydroxylase CAH in routine tertiary care, better "clinical control" (including growth velocity) and controlled androstenedione were reported to predict better bone age control, while older age was linked to lower odds of bone age control. The same study reported that adrenal crises occurred in 20.8% of participants, and that biochemical control was associated with treatment compliance. Taken together, these results underline how growth patterns, hormone levels, and bone age often move together in pediatric CAH monitoring, even though this study could not prove cause and effect. [1]

Saliva testing showed a strong relationship with blood testing for several commonly followed CAH hormones in 45 children with classic CAH, including 17-hydroxyprogesterone and androstenedione in both prepubertal and pubertal groups. Some hormones had weaker relationships, which the authors noted could relate to sample size and the need for larger studies to translate saliva numbers into blood-equivalent values. This supports saliva as a possible less invasive way to track certain hormone patterns, but it is not yet a complete replacement for blood testing in all situations. [2]

For bone age, an external validation study of an open-source automated system (Deeplasia) reported lower error than individual human raters when compared against Greulich-Pyle based expert readings across two pediatric cohorts that included rare endocrine conditions such as CAH. Accuracy remained high in the cohort that included endocrine disorders, and performance dropped in some conditions where hand bones can look less typical. This suggests automated reading could help standardize bone age assessment, but it is still anchored to the same reference method and is not a perfect "ground truth." [3]

For families, the main update is that multiple studies are trying to make monitoring easier to do and easier to interpret, especially in children where growth and puberty affect many measurements. Right now, these findings mainly add understanding about which measures tend to line up (growth, certain hormones, and bone age) and where newer approaches like saliva testing or automated bone age reading might fit in the future if confirmed and adopted. What remains uncertain is how well these approaches perform over time for the same child, and how they would be used alongside existing clinic routines across different countries and health systems. [1] [2] [3]

This month, several studies focused on recognizing CAH accurately and understanding how it can relate to broader health and development. Work ranged from newborn screening records, to detailed descriptions of rare CAH subtypes and their genetic causes, to studies describing blood pressure problems in a CAH-related condition (PORD). Two studies also looked at day-to-day functioning in children with classic CAH, finding a mixed picture with some areas similar to peers and some areas lower than expected. [4] [5] [6] [7] [8]

In a single-center report of 12 Chinese patients with rarer CAH subtypes, the authors described clinical and hormone patterns that helped distinguish forms such as 11beta-hydroxylase deficiency, lipoid CAH, aldosterone synthase deficiency, and 17alpha-hydroxylase deficiency. They also reported six newly identified disease-causing genetic variants across several CAH-related genes. The study adds to the idea that "CAH" is a group of conditions that can look quite different, and that genetics plus hormone patterns can help clarify the exact subtype. [5]

A study of newborn screening records from one Eastern Indian province reported results from 3210 screened newborns and noted that 17-hydroxyprogesterone (a screening marker used for CAH) was higher in males. The report was not focused on CAH alone, but it highlights that sex differences in screening markers can matter when interpreting population-level screening results. The study also described the overall frequency of inherited disorders detected in that screening effort, emphasizing the implementation side of early detection. [4]

In PORD (P450 oxidoreductase deficiency), a CAH-related condition, a small case-control study found higher blood pressures and a higher rate of hypertension in 10 affected individuals compared with 41 matched controls. The same study reported small-vessel changes seen by nailfold capillaroscopy and higher thromboxane B2, a blood marker related to vessel tone, while some other vasoactive markers did not differ. This builds a clearer picture that vascular and blood pressure issues can be a prominent feature in PORD, although the study cannot show what would change these findings. [6]

Two studies in children and adolescents with classic CAH added to the picture of how children are doing beyond hormone numbers. In 34 children with classic CAH, average scores were lower than population norms in gross motor skills in the youngest group and in specific learning and memory areas plus adaptive behavior in older children. In a separate study of 25 youth with CAH compared with 25 controls, overall quality of life scores were similar, but the pattern differed by age, with lower school functioning reported in adolescents. [7] [8]

For patients and caregivers, these studies mainly add detail to the bigger picture of "getting the label right" and noticing areas that may deserve attention over the long term, like blood pressure in PORD and school functioning in adolescents. None of these studies on their own changes what a person should do, but they help clarify what researchers are measuring and which differences show up repeatedly in groups of patients. Important uncertainties remain, including how well these findings apply to other populations and what factors (such as treatment history, puberty timing, or school supports) might explain the mixed developmental and quality-of-life patterns. [5] [4] [6] [7] [8]

This month included two studies that built "normal range" charts for hormones that are often part of CAH evaluation and follow-up. One study focused on ACTH and renin in healthy children and teens, and the other mapped several androgens in healthy adults. The shared message is that age, puberty, sex, and hormone exposure (like oral contraceptives) can shift these numbers, which can affect how a single test result is interpreted. [9] [10]

In 529 healthy Danish youths, ACTH levels were broadly similar between sexes, but were higher in pubertal males than prepubertal males in some analyses, and renin tended to be lower in puberty in both sexes. Renin SD scores were also lower in oral contraceptive users than non-users, while ACTH SD scores did not differ between those groups. This helps explain why the same ACTH or renin value may not mean the same thing at different ages or pubertal stages. [9]

In 266 healthy Chinese adults, researchers established sex- and age-specific reference intervals for several so-called "backdoor pathway" androgens, which are alternative routes the body can use to make active androgens. They reported clear differences between males and females, and additional age-group differences for some steroids. For CAH, this kind of work is mainly foundational, because it provides comparison ranges that future patient studies can use to interpret these steroid levels. [10]

These studies matter mostly as background that can make hormone testing easier to interpret over time, especially during puberty or when taking hormones like oral contraceptives. The information may matter later if clinics or laboratories adopt these reference ranges for reporting results or for newer steroid panels. What remains uncertain is how directly these reference ranges translate across different countries, testing platforms, and everyday clinic timing, since hormone levels can change during the day. [9] [10]

This month, case reports highlighted how CAH can present in ways that look like other conditions and how individual care situations can be complex. Two reports focused on testicular adrenal rest tumors (TARTs), emphasizing that imaging can mimic cancer but may change with corticosteroid treatment. Other reports described adult genital surgery in CAH, an overlap of non-classic CAH with autoimmune type 1 diabetes in one teenager, and two men with a milder form of lipoid adrenal hyperplasia due to STAR gene variants. [11] [12] [13] [14] [15]

Across the two TART case reports, the common message was that these testicular masses can show strong signals on imaging and may be mistaken for malignancy, but they were reported to shrink or lose metabolic activity after corticosteroid treatment. One report described FDG PET/CT uptake that resolved completely after therapy, and another described a decrease in testicular size on ultrasound after dexamethasone over 6 months. These single-patient observations support the idea that TART activity can be driven by high ACTH levels in CAH, while also showing why careful interpretation of imaging is important. [11] [12]

One adult case report described a 24-year-old with CAH who underwent one-stage feminizing genitoplasty, with the authors emphasizing feasibility in adulthood but without long-term outcomes. Another report described a teenager with non-classic CAH who later developed antibody-positive type 1 diabetes, raising a hypothesis about shared genetic neighborhood effects but not establishing cause. Two additional cases described late-onset, non-classic lipoid adrenal hyperplasia in 46,XY males linked to STAR variants, illustrating that milder forms can present later and still vary even with related mutations. [13] [14] [15]

Case reports do not tell what is typical, but they can spotlight situations that patients may encounter, such as confusing imaging results for testicular masses or complex decisions around surgery in adulthood. This month, the cases mainly reinforce that CAH-related findings can look like other diseases on scans, and that rare genetic subtypes and overlapping endocrine conditions can occur. What remains uncertain is how often these scenarios happen and which approaches work best across larger groups, because each report describes only 1 or 2 people. [11] [12] [13] [14] [15]